IL-6-induced anaemia in rats: Possible pathogenetic implications for anaemia observed in chronic inflammations

Clinical and Experimental Immunology

Volumn 103, Issue 2, 1996, Pages 328-334

  Jongen Lavrencic, M ^a   Peeters, H R M ^a   Rozemuller, H ^b   Rombouts, W J C ^b   Martens, A C M ^b   Vreugdenhil, G ^c   Pillay, M ^a   Cox, P H ^a   Bijser, M ^a   Brutel, G ^a   Breedveld, F C ^d   Swaak, A J G ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^c ST JOSEPH HOSPITAL   (Netherlands)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Anaemia; Anaemia of chronic disease; Chronic disease; IL 6

Indexed keywords

CYTOKINE; ERYTHROPOIETIN; INTERLEUKIN 6; TECHNETIUM 99M;

ANEMIA; ANIMAL EXPERIMENT; ARTICLE; BLEEDING; CONTROLLED STUDY; ERYTHROPOIESIS; FEMALE; INTESTINE; NONHUMAN; PRIORITY JOURNAL; RAT; RHEUMATOID ARTHRITIS;

EID: 9044236905     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.1996.d01-622.x     Document Type: Article

References (32)

1. Means RT Jr, Krantz SB. Progress in understanding the pathogenesis of the anemia of chronic disease. Blood 1992; 80:1639-47.
2. Baer AN, Dessypris EN, Krantz SB. The pathogenesis of anemia in rheumatoid arthritis: a clinical and laboratory analysis. Semin Arthritis Rheum 1990; 19:209-23.
3. Vreugdenhil G, Wognum AW, Van Eijk HG, Swaak AJ. Anaemia in rheumatoid arthritis: the role of iron, vitamin B12, and folic acid deficiency, and erythropoictin responsiveness. Ann Rheum Dis 1990; 49:93-98.
4. Kobune M, Kohgo Y, Kato J, Miyazaki F, Niitsu Y. Interleukin-6 enhances hepatic transferrin uptake and ferritin expression in rats. Hepatology 1994; 19:1468-75.
5. Hirayama M, Kohgo Y, Kondo H et al. Regulation of iron metabolism in HepG2 cells: a possible role for cytokines in the hepatic deposition of iron. Hepatology 1993; 18:874-80.
6. Means RT Jr, Dessypris EN, Krantz SB. Inhibition of human colony-forming-unit erythroid by tumor necrosis factor requires accessory cells. J Clin Invest 1990; 86:538-41.
7. Jongen-Lavrencic M, Peeters HRM, Backx B, Touw IP, Vreugdenhil G, Swaak AJG. r-h-Erythropoietin counteracts the inhibition of in vitro erythropoiesis by tumour necrosis factor alpha in patients with rheumatoid arthritis. Rheumatol Int 1994; 14:109-13.
8. Vreugdenhil G, Lowenberg B, Van Eijk HG, Swaak AJ. Tumor necrosis factor alpha is associated with disease activity and the degree of anemia in patients with rheumatoid arthritis. Eur J Clin Invest 1992; 22:488-93.
9. Jelkmann WE, Fandrey J, Frede S, Pagel H. Inhibition of erythropoietin production by cytokines. Implications for the anemia involved in inflammatory states. Ann NY Acad Sci 1994; 718: 300-9.
10. Kishimoto T. The biology of interleukin-6. Blood 1989; 74:1-10.
11. Vreugdenhil G, Lowenberg B, Van Eijk HG, Swaak AJ. Anaemia of chronic disease in rheumatoid arthritis. Raised serum interleukin-6 (IL-6) levels and effects of IL-6 and anti-IL-6 on in vitro erythropoiesis. Rheumatol Int. 1990; 10:127-30.
12. Herodin F, Mestrics J, Janodet D et al. Recombinant glycosylated human interleukin-6 accelerates peripheral blood platelet count recovery in radiation-induced bone marrow depression in baboons. Blood 1992; 808:688-95.
13. Asano S, Okano A, Ozawa K et al. In vivo effects of recombinant human interleukin-6 in primates: stimulated production of platelets. Blood 1990; 75:1602-5.
14. Sun WH, Binkley N, Bidwell DW, Ershler WB. The influence of recombinant human interleukin-6 on blood and immune parameters in middle-aged and old rhesus monkeys. Lymphokine Cytokine Res 1993; 12:449-55.
15. van Gameren MM, Willemse PHB, Mulder NH et al. Effects of recombinant human intcrlcukin-6 in cancer patients: a phase I-II study. Blood 1994; 84:1434-41.
16. Weber J, Yang JC, Topalian SL et al. Phase I trial of subcutaneous interleukin-6 in patients with advanced malignancies. J Clin Oncol 1993; 11:499-506.
17. Nicken J, Mulder NH, Buter J et al. Recombinant human interleukin-6 induces a rapid and reversible anemia in cancer patients. Blood 1995; 86:900-5.
18. Barrera P, Boerbooms AMTh, Janssen EM et al. Circulating soluble tumor necrosis factor receptors, interleukin-2 receptors, tumor necrosis factor α, and interleukin-6 levels in rheumatoid arthritis. Arthritis Rheum 1993; 36:1070-9.
19. Manicourt DH, Triki R, Fukuda K, Devogelaer JP, de Deuxchaisnes CN, Thonar EJMA. Levels of circulating tumor necrosis factor α and interleukin-6 in patients with rheumatoid arthritis. Arthritis Rheum 1993; 36:490-9.
20. Wendling D, Racadot E, Wijdenes J. Treatment of severe rheumatoid arthritis by anti-interlcukin-6 monoclonal antibodies. J Rheumatol 1993; 20:259-62.
21. Beck JT, Hsu S, Wijdenes J et al. Alleviation of systhemic manivestation of Castleman's disease by monoclonal anti-interleukin-6 antibody. New Engl J Med 1994; 330:602-5.
22. Helle M, Boeije L, De Groot ER, De Vos A, Aarden LA. Sensitive ELISA for interleukin-6. Detection of IL-6 in biological fluids: synovial fluids and sera. J Immunol Methods 1991; 138:42-56.
23. + bone marrow cells, differentiating monomycloid progenitors, and mature blood cell subsets. Blood 1994; 84:764-74.
24. Vreugdenhil G, Kroos MJ, Van Eijk HG, Lowenberg B, Swaak AJ. Impaired iron uptake and transferrin binding by erythroblasts in the anaemia of rheumatoid arthritis. Br J Rhcumatol 1990; 29:335-9.
25. Pojda Z, Tsuboi A. In vivo effects of human recombinant interleukin 6 on hemopoietic stem and progenitor cells and circulating blood cells in normal mice. Exp Hematol 1990; 18:1034-7.
26. Hill RJ, Warren MK, Stenberg P et al. Stimulation of mega-karyocytopoiesis in mice by human rccombinant interleukin-6. Blood 1991; 77:42-48.
27. Klausner RD, Harford JB. Cis-trans models for post-transcriptional gene regulation. Science 1989; 246:870-2.
28. Roodman GD, Bird A, Hutzler D, Montgomery W. Tumor necrosis factor-alpha and hematopoietic progenitors: effects of tumor necrosis factor on the growth of erythroid progenitors CFU-E and BFU-E and the hematopoietic cell lines K562, HL60, and HEL cells. Exp Hematol 1987; 15:928-35.
29. Dinant HJ, de Maat CEM. Erythropoiesis and mean red-cell lifespan in normal subjects and in patients with the anaemia of active rheumatoid arthritis. Br J Hacmatol 1978; 39:437-44.
30. Patton JS, Peters PM, McCabe J et al. Development of partial tolerance to the gastrointestinal effects of high doses of recombinant tumor necrosis factor-α in rodents. J Clin Invest 1987; 80:1587-96.
31. Remick DG, Kuntel RG, Larrick JW, Kuntel SL. Acute in vivo effects of human recombinant tumor necrosis factor. Lab Invest 1987; 56:583-90.
32. Butler LD, Layman NK, Cain RL et al. Interleukin-1 induced pathophysiology: induction of cytokinc development of histopathologic changes, and immunopharmacologic intervention. Clin Immunol Immunopathol 1989; 53:400-21.